Tyna Moore: Microdosing GLP-1 quietly heals the brain

Standard Ozempic protocols titrate from 0.25 mg up to ~2.4–2.5 mg per week in 16 weeks, often crushing appetite and causing GI side effects. Moore instead uses compounded semaglutide at a fraction of the starting dose (below 0.25 mg), often with insulin syringes, and titrates slowly—aiming to stay just below the threshold of side effects. She reports gains in cognitive clarity, reduced chronic pain, normalized bowels, improved skin, and better mood in herself, her mother (Crohn’s + early dementia), daughter (PCOS, cystic acne), and patients, without devastating appetite or muscle.

GLP‑1 is a peptide hormone made in the gut and brain; semaglutide is bioidentical with modifications to extend its half‑life. Moore points to literature on GLP‑1’s neuroprotective, anti‑inflammatory, and neuroplastic effects, including benefits in models of Parkinson’s, Alzheimer’s, depression, anxiety, and addiction. She frames many downstream issues—autoimmunity, hormonal disruption, chronic pain—as consequences of an ‘inflamed brain’ and dysregulated neuro‑immune signaling that GLP‑1 can help calm.

Moore notes data suggesting only about 6.8% of U.S. adults were metabolically healthy even before COVID, with insulin resistance and fatty infiltration of liver, muscle, and pancreas normalized over time. She argues that current medicine waits until type 2 diabetes appears, then adds lifelong drugs, instead of intervening in the 15–20 year prediabetic window with lifestyle and targeted therapies like GLP‑1 to reverse dysfunction and prevent organ damage.

Her six pillars include: (1) strength training to build/maintain muscle as ‘the currency of metabolic health’; (2) daily walking, ideally three 10‑minute walks with morning, midday, and late‑afternoon light; (3) protein‑forward, colorful whole‑food eating, ~30 g protein per meal; (4) sleep hygiene and circadian rhythm via light management and reduced screens; (5) mindset and goal‑oriented behavior; (6) environmental/behavioral detox—cutting ultra‑processed foods and reducing personal‑care chemical exposure. She insists GLP‑1 use without these pillars is what leads to rapid weight loss, muscle loss, gallstones, and mood collapse.

Media stories highlight gastroparesis, bowel obstruction, pancreatitis, and severe depression. Moore contends many of these patients already have subclinical gastroparesis, fatty pancreas, gallbladder sludge, or hormonal fragility due to chronic metabolic disease and then are pushed rapidly up to high doses that induce extreme caloric restriction. She argues tiny doses plus slow titration and close monitoring greatly reduce risk and that emerging analyses find much lower safety signals than headlines suggest.